🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BSH Lymphoma SIG MDT Dilemmas Live webinar Thurs 10Oct 1800-19:30 Management of asymp low tumour burden FL: Kirit Ardeshna & David Tucker Rx PMBL Andy Davies & ⁦Nicolas Martinez 🇨🇴🇨🇴⁩ NLPHL Rx dilemmas ⁦Pam McKay⁩ ⁦⁦Graham Collins⁩ b-s-h.org.uk/education/conf…

Impressive outcomes for ACOPP in older pts with Hodgkin. 41pts, 2y PFS 83%. Some toxicity seen though - 34% FN. great work from Matt Wilson and Pam McKay and coworkers. #ISHL13 #lymsm

Clinical trial protocol presented by Dr. Steiner at #ISHL13: randomized trial of rituximab versus mosunetuzumab in first-line stage IB to IV NLPHL. #lymsm #NLPHLsm

New standard of care for older Hodgkin Lymphoma patients since ASH 2023 with Nivolumab + AVD Graham Collins presenting background and alternatives, we still wait for nivo access in many countries! #ISHL13, #lymsm RATiFY trial will bring knowledge even further!

With a great summary

Thanks Graham!

Thanks to Rajana Advani for including our data in the Best of #ISHL13 session. What a phenomenal three days- so much exciting science and practice-changing trial data, and so many new friends made with exciting future collaboration potential.

2-The prognostic score incorporated ECOG, hemoglobin, LDH, number of extranodal sites and time from CAR-T to PD (all assessed at time of PD to CART) Median OS in the 4 risk groups was 15.7, 7.1, 1.8 and 1.0 months. PC-PI outperformed IPI and R-IPI in this setting.

#WiLingWednesdays #IndolentLymphoma #webinar Thank you Jessica Okosun & Carla Casulo, MD - excellent presentations and discussion! 👉watch video recording us06web.zoom.us/rec/share/_cED… With thanks to Gilead Sciences #IFLI Eli Lilly and Company Lymphoma Australia #lymphoma #lymsm #WomeninLymphoma

#ASH24 mantle cell lymphoma abstracts I'm looking forward to: 1. ENRICH ash.confex.com/ash/2024/webpr… n=397 🇬🇧led academic ph3 RCT ibrutinib rituximab vs BR/RCHOP IR superior to R-chemo (HR 0.69) though this differed by chemo arm (HR 0.37 RCHOP, 0.91 BR). Practice changing? #lymSM

BSH - Haematology Nimish shah David Cutter Pam McKay Matt Wilson Graham Collins I am also hopeful that in the future we will be routinely able to use BV-AVD, BrECADD and Nivo-AVD in the front-line setting to avoid giving bleomycin to patients treated with curative intent.

Great work from Aisling Barrett - a rising star in lymphoma research. Bleomycin is still widely used in many countries for Hodgkin lymphoma (hopefully for not too much longer). An excellent good practice paper for using it safely.

Agree. Huge contribution from Aisling in many aspects of HL research/ management. Well done Aisling

Many congratulations to Kate Cwynarski for publishing this fantastic early phase CAR T trial in PTCL. Looking forward to seeing its further development in such a difficult disease. #lymsm

Really nice study showing continued cardiovascular risk in Hodgkin patients after modern systemic therapies.

Delighted to share the practice-changing #STARGLO study manuscript at The Lancet today. Transplant-ineligible DLBCL should no longer be considered a palliative scenario #lymsm Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-G... sciencedirect.com/science/articl…

Would you like to improve your #Sleep? Join our next Special Focus Support Meeting 👉 lymphoma-action.org.uk/events/special… On Thursday 12 December, you can hear from Dr Mike Scanlan about getting a good night's sleep, and share experiences with other people affected by #Lymphoma.

Goldstein: factors predicting EOT MRD+ DLBCL - IPI did not associate with MRD+ at EOT - Stage, baseline ctDNA and interim assessments did associate - EOT MRD+ highly prognostic irrespective of IPI group #ASH24 #lymsm

Great to see this published! Effect of replacing procarbazine for dacarbazine in escBEACOPP for Hodgkin Rx. Huge beneficial effect on genotoxicity. Really no role for procarbazine in front line Hodgkin. Congrats to Anna Santasieri & George Follows. #lymsm thelancet.com/journals/lanon…

Great work. Supports the UK practice of using esc BEACOPDac in preference to escBEACOPP